Published in Genet Med on January 01, 2009
Ohio Colorectal Cancer Prevention Initiative (OCCPI) | NCT01850654
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med (2009) 3.57
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol (2015) 3.19
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol (2012) 2.40
The genomic applications in practice and prevention network. Genet Med (2009) 2.39
Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers. Genet Med (2010) 2.07
Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology (2014) 1.93
Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther (2014) 1.93
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Personalized medicine: new genomics, old lessons. Hum Genet (2011) 1.85
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol (2010) 1.69
The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila) (2011) 1.66
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Translational research in cancer genetics: the road less traveled. Public Health Genomics (2009) 1.65
Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet (2009) 1.62
Nurses transforming health care using genetics and genomics. Nurs Outlook (2010) 1.54
Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience. Dig Dis Sci (2014) 1.50
Towards an evidence-based process for the clinical interpretation of copy number variation. Clin Genet (2011) 1.50
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genet Med (2011) 1.37
Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med (2011) 1.36
Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol (2013) 1.33
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol (2014) 1.26
Multilevel research and the challenges of implementing genomic medicine. J Natl Cancer Inst Monogr (2012) 1.21
Public health action in genomics is now needed beyond newborn screening. Public Health Genomics (2012) 1.17
Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep (2012) 1.16
Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev (2011) 1.13
How can polygenic inheritance be used in population screening for common diseases? Genet Med (2013) 1.10
Screening for Lynch syndrome: it is time to shift the focus. Dig Dis Sci (2015) 1.10
Economic evaluation of genetic screening for Lynch syndrome in Germany. Genet Med (2015) 1.10
Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. Genet Med (2013) 1.04
Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how? Hum Genet (2009) 1.03
Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer (2013) 1.03
Communication, encouragement, and cancer screening in families with and without mutations for hereditary nonpolyposis colorectal cancer: a pilot study. Genet Med (2009) 1.03
Lynch syndrome: an updated review. Genes (Basel) (2014) 1.02
Genetics in population health science: strategies and opportunities. Am J Public Health (2013) 1.02
Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol (2013) 1.02
Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. Genet Med (2014) 1.00
Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med (2013) 0.95
Closing the gap between knowledge and clinical application: challenges for genomic translation. PLoS Genet (2015) 0.94
MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet (2012) 0.94
Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico. Fam Cancer (2010) 0.94
The influence of health care policies and health care system distrust on willingness to undergo genetic testing. Med Care (2012) 0.92
Colorectal Cancer Biomarkers: Where Are We Now? Biomed Res Int (2015) 0.92
Patterns of cancer genetic testing: a randomized survey of Oregon clinicians. J Cancer Epidemiol (2012) 0.91
Impact of age cutoffs on a lynch syndrome screening program. J Oncol Pract (2012) 0.90
Colon cancer screening practices and disclosure after receipt of positive or inconclusive genetic test results for hereditary nonpolyposis colorectal cancer. Cancer (2009) 0.90
Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS One (2015) 0.89
Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Semin Diagn Pathol (2015) 0.89
Application of molecular diagnostics for the detection of Lynch syndrome. Expert Rev Mol Diagn (2010) 0.89
Genetic testing for lynch syndrome in individuals newly diagnosed with colorectal cancer to reduce morbidity and mortality from colorectal cancer in their relatives. PLoS Curr (2011) 0.88
Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract (2012) 0.87
Implementation of routine screening for Lynch syndrome in university and safety-net health system settings: successes and challenges. Genet Med (2013) 0.86
Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemp Clin Trials (2014) 0.86
Evaluating the utilization of educational materials in communicating about Lynch syndrome to at-risk relatives. Fam Cancer (2014) 0.85
Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer (2015) 0.85
Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer. Genet Test Mol Biomarkers (2014) 0.85
Applicability of next generation sequencing technology in microsatellite instability testing. Genes (Basel) (2015) 0.85
Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila) (2014) 0.85
The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. Appl Clin Genet (2014) 0.84
Endometrial and ovarian cancer in lynch syndrome. Clin Colon Rectal Surg (2012) 0.84
Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer (2012) 0.84
How do we approach the goal of identifying everybody with Lynch syndrome? Fam Cancer (2013) 0.84
A proposed clinical decision support architecture capable of supporting whole genome sequence information. J Pers Med (2014) 0.83
Hereditary gastrointestinal cancer syndromes. Gastrointest Cancer Res (2011) 0.83
Creation of a network to promote universal screening for Lynch syndrome: the LynchSyndrome Screening Network. J Genet Couns (2014) 0.83
Reflex testing for Lynch syndrome: if we build it, will they come? Lessons learned from the uptake of clinical genetics services by individuals with newly diagnosed colorectal cancer (CRC). Fam Cancer (2014) 0.82
Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genet Med (2015) 0.82
Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). J Med Genet (2014) 0.82
KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol (2015) 0.81
High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study. BMC Cancer (2012) 0.81
Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. Gynecol Oncol (2015) 0.81
When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives. Healthcare (Basel) (2015) 0.81
Explanations of risk in families without identified mutations for hereditary nonpolyposis colorectal cancer. J Nurs Scholarsh (2010) 0.81
Health behaviors in patients and families with hereditary colorectal cancer. Clin Colon Rectal Surg (2012) 0.80
Colorectal cancer survivors' interest in genetic testing for hereditary cancer: implications for universal tumor screening. Genet Test Mol Biomarkers (2012) 0.80
Evaluating genomic tests from bench to bedside: a practical framework. BMC Med Inform Decis Mak (2012) 0.80
Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers. Eur J Hum Genet (2013) 0.80
Advances in the study of Lynch syndrome in China. World J Gastroenterol (2015) 0.80
Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives. PLoS Curr (2013) 0.80
Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer (2015) 0.80
The evolution of personalized cancer genetic counseling in the era of personalized medicine. Fam Cancer (2012) 0.79
The future of clinical cancer genomics. Semin Oncol (2016) 0.79
Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer (2016) 0.78
Testing women with endometrial cancer for lynch syndrome: should we test all? J Adv Pract Oncol (2013) 0.78
Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagn Pathol (2017) 0.78
Prevalence and correlates of receiving and sharing high-penetrance cancer genetic test results: findings from the Health Information National Trends Survey. Public Health Genomics (2015) 0.78
Genomics in Public Health: Perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC). Healthcare (Basel) (2015) 0.78
Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist. Gynecol Oncol (2013) 0.78
Interest and informational preferences regarding genomic testing for modest increases in colorectal cancer risk. Public Health Genomics (2014) 0.78
Diagnostic Approach to Hereditary Colorectal Cancer Syndromes. Clin Colon Rectal Surg (2015) 0.78
The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program. Hered Cancer Clin Pract (2010) 0.78
Communication and technology in genetic counseling for familial cancer. Clin Genet (2013) 0.78
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet (2007) 4.62
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med (2009) 3.57
Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology (2006) 2.34
Benchmark for evaluating the quality of DNA sequencing: proposal from an international external quality assessment scheme. Clin Chem (2006) 1.85
Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term. World J Gastroenterol (2006) 1.70
Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med (1998) 1.67
Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer (2005) 1.58
Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut (2003) 1.55
A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer (1998) 1.49
Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer (2005) 1.42
Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing. Genet Med (2003) 1.21
Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma. Community Genet (2006) 1.03
Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care (2007) 1.03
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med (2009) 2.33
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med (2009) 1.94
Recommendations from the EGAPP Working Group: genomic profiling to assess cardiovascular risk to improve cardiovascular health. Genet Med (2010) 0.93